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Abstract The incidence of melanoma continues to dra-
matically increase in most Western countries with
predominantly Caucasian populations. However, only
limited therapies for the metastatic stage of the disease are
currently available. The main purpose of this study is to
determine approaches that can substantially increase
radiosensitivity of melanoma cells. The PI3K-AKT, NF-jB
and COX-2 pathways, which are involved in the radio-
protective response, are highly active in melanoma cells.
Pharmacological suppression of COX-2 and PI3K-AKT, or
RNAi-mediated knockdown of COX-2, substantially
increased levels of G2/M arrest of the cell cycle and
decreased clonogenic survival of gamma-irradiated mela-
nomas, predominantly via a necrotic mechanism. On the
other hand, resveratrol, a polyphenolic phytoalexin, selec-
tively targets numerous cell signaling pathways, decreasing
clonogenic survival primarily via an apoptotic mechanism.
In melanoma cells, resveratrol inhibits STAT3 and NF-jB-
dependent transcription, culminating in suppression of
cFLIP and Bcl-xL expression, while activating the MAPK-
and the ATM-Chk2-p53 pathways. Resveratrol also
upregulates TRAIL promoter activity and induces TRAIL
surface expression in some melanoma cell lines, resulting
in a rapid development of apoptosis. Sequential treatment
of melanoma cells, first with c-irradiation to upregulate
TRAIL-R surface expression, and then with resveratrol to
suppress antiapoptotic proteins cFLIP and Bcl-xL and
induce TRAIL surface expression, had dramatic effects on
upregulation of apoptosis in some melanoma lines,
including SW1 and WM35. However, for melanoma lines
exhibiting suppressed translocation of TRAIL to the cell
surface, a necrotic mechanism of cell death was primarily
involved in radiation response. Hence, surface expression
of TRAIL induced by resveratrol appears to be a decisive
event, one which determines an apoptotic versus a necrotic
response of melanoma cells to sequential treatment.
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Introduction
Ionizing radiation and chemotherapy are two predominant
therapeutic modalities used for cancer treatment. Cytotoxic
effects of most conventional anti-cancer drugs (for example,
cisplatin and etoposide) and ionizing radiation are mediated
through pleotropic mechanisms, which include interaction
and damage of genomic DNA followed by activation of
DNA damage induced signaling pathways (both p53-
dependent and p53-independent). These pathways culminate
in cell cycle arrest and/or induction of cell death by apop-
tosis, necrosis, autophagy or mitotic catastrophe [1, 2]. In this
scenario, the Bcl-2 family members with prosurviving
functions, such as Bcl-xL, play a crucial role by neutralizing
function of the proapoptotic BH3-only proteins, resulting in
an inhibition of transmission of an apoptotic signal to the
executor proteins BAX and BAK and suppression of the
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mitochondrial death pathway [3]. A role of transcription
factor NF-jB, which controls expression of Bcl-xL and
many other proteins with survival functions, is well estab-
lished for positive regulation of radioprotection in normal
and cancer cells [4]. On the other hand, alternative therapies,
which have been suggested for induction of apoptosis in
cancer cells, are often based on direct activation of extrinsic
death signaling pathways. Examples of this strategy include
the use of recombinant death ligands of the TNF superfamily,
such as Fas Ligand and TRAIL, or the correspondent
agonistic monoclonal antibodies to the death receptors,
Fas, TRAIL-R1/DR4 or TRAIL-R2/DR5 [5, 6]. Targeting
TRAIL-receptor mediated signaling pathways for induction
of apoptosis is currently under evaluation in multiple clinical
trials for several types of cancer [7, 8]. Finally, combined
modality treatments, which include c-irradiation and specific
inhibitions of the cell survival pathways, appear to be
promising approaches for the control and suppression of
cancer development [9, 10].
Melanoma, the most aggressive form of skin cancer, is
known to be relatively resistant to conventional radiotherapy
and chemotherapy. In the USA, approximately 60,000 new
cases were diagnosed and 8,100 deaths occurred in 2007
(ACS, 2007). However, only limited therapies for the met-
astatic stage of the disease are currently available. Various
attempts have been made to achieve high levels of apoptosis
in response to treatment for this type of cancer. The main
purpose of this study is to ascertain approaches that can
substantially increase radiosensitivity of melanoma cells by
inhibiting activity/expression levels of the main regulators of
the general cell survival, COX-2 [11], AKT [12] or by
simultaneous expression of endogenous death ligand and
death receptor, TRAIL and TRAIL-Receptor [5].
Most melanomas possess non-mutated wild-type p53,
which functions as a transcription factor controlling TRAIL-
R2/DR5, FAS, BAX, BID, PUMA, NOXA and p21-WAF gene
expression and mediating the cell cycle arrest or/and apop-
tosis [13, 14]. However, p53 does not appear to play a direct
role in executive regulation of apoptosis via p53-dependent
BH3-only proteins (PUMA, NOXA) or p53-dependent BAX
in many melanoma lines. This lack of proapoptotic p53
influence is due to downstream protective mechanisms, such
as cancer-specific suppression of mitochondrial function and
the mitochondrial death pathway [15, 16] that was often
observed in advanced melanomas [17].
Materials and methods
Materials
Resveratrol (RV) was obtained from Sigma (St. Louis,
MO, USA). Human soluble Killer-TRAIL (recombinant)
was purchased from Alexis (San Diego, CA, USA). JNK
inhibitor SP600125 and IKK-NF-jB inhibitor BAY
11-7082 were obtained from Biomol (Plymouth Meeting,
PA, USA); PI3K inhibitor LY294002, MEK inhibitor
U0126, MAPK p38 inhibitor SB203580 and caspase inhib-
itors zVAD-fmk were purchased from Calbiochem (La Jolla,
CA, USA). COX-2 inhibitor NS398 was obtained from
Cayman Chemical Company (Ann Arbor, Michigan, USA).
Cell lines
Human melanoma cell lines LU1205 (also known as
1205lu), WM9 and WM35 [18], as well as HHMSX, LOX,
and mouse melanoma line SW1 were maintained in a
DMEM medium supplemented with 10% fetal bovine
serum (FBS), L-glutamine and antibiotics.
Irradiation procedures
To determine sensitivity to c-rays, plated melanoma cells
were exposed to radiation from a Gammacell 40 137Cs
irradiator (dose rate, 0.82 Gy/min) at Columbia University.
Six to 24 h after irradiation, cells were analyzed by flow
cytometry or underwent additional treatment.
FACS analysis of TRAIL and TRAIL-R2/DR5 levels
Surface levels of TRAIL and TRAIL-R2/DR5 on human
melanomas were determined by staining with a PE-conju-
gated anti-human-TRAIL or anti-human DR5 mAb (R&D
System, Minneapolis, MN, USA and eBioscience, San
Diego, CA, USA) and subsequent flow cytometry.
PE-conjugated nonspecific mouse IgG1 was used as an
immunoglobulin isotype control. A FACS Calibur flow
cytometer (Becton Dickinson, Mountain View, CA, USA)
and the CellQuest program were used to perform flow
cytometric analysis. All experiments were independently
repeated 3–5 times.
Transfection and luciferase assay
A NF-jB luciferase reporter containing two jB binding
sites, a Jun2-Luc reporter and empty vector tk-Luc [19], and
a STAT-Luc reporter containing three repeats of GAS sites
from the Ly6A/E promoter, were used to determine NF-jB,
AP-1 and STAT transactivation, respectively. Additional
reporter constructs used included: 1.5 kb TRAIL-promoter-
Luc [20], 1 kb cFLIP-promoter-Luc [21, 22] and p53RE-Luc
[23]. Transient transfection of different reporter constructs
(1 lg) together with pCMV-bgal (0.25 lg) into 5 9 105
melanoma cells was performed using Lipofectamine (Life
Technologies-Invitrogen, Carlsbad, CA, USA). Proteins
were prepared for b-Gal and luciferase analysis 16 h after
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transfection. Luciferase activity was determined using the
Luciferase assay system (Promega, Madison, WI, USA) and
was normalized based on b-galactosidase levels. Since res-
veratrol was known to partially inhibit enzymatic activity of
firefly luciferase [24], a ratio of the specific luciferase
reporter activity to luciferase activity driven by the empty
tk-Luc vector in a mock control culture was determined for
analysis.
COX-2 suppression by RNAi
The pSUPER retro RNA interference (RNAi) system
(Oligoengine, Seattle, WA, USA), which has been utilized
for the production of small RNAi transcripts, was used to
suppress cFLIP expression. Three variants of RNAi, of 19
nucleotides each, were designed to target human COX-2 and
expressed using vector pSUPER.retro.puro (pSR-puro).
RNAi COX-2-379 (CCUUCUCUAACCUCUCCUA) was
most efficient in corresponding mRNA targeting.
Apoptosis studies
Cells were exposed to soluble TRAIL (50 ng/ml) alone,
resveratrol (RV) (25–100 lM) or TRAIL (50 ng/ml) in
combination with cycloheximide (2 lg/ml). Apoptosis was
assessed by quantifying the percentage of hypodiploid
nuclei undergoing DNA fragmentation or by quantifying
the percentage of Annexin-V-FITC-positive cells (BD
Pharmingen, San Diego, CA, USA). Flow cytometric
analysis was performed on a FACS Calibur flow cytometer
(Becton Dickinson, San Jose, CA, USA) using the Cell-
Quest program.
Clonogenic survival assay
Cells (500/plate) were placed in triplicate on 10 cm- plates
16 h before treatment. For analysis of clonogenic survival
of melanoma cells after treatment (24 h) with TRAIL,
resveratrol (RV) or their combination, colonies were
stained with crystal violet solution 12 days after treatment.
The percentage of colony-forming efficiency (relative to
values of untreated control cells) was calculated.
Western blot analysis
Total cell lysates (50 lg protein) were resolved on 10%
SDS-PAGE, and processed according to standard proto-
cols. The antibodies (Abs) used for Western blotting
included: monoclonal anti-b-Actin (Sigma, St. Louis, MO,
USA), monoclonal anti-FLIP (NF6) (Axxora, San Diego,
CA, USA), monoclonal anti-XIAP (BD Biosciences, San
Jose, CA, USA), monoclonal anti-p21-WAF1 (Cell Sig-
naling Beverly, MA, USA); polyclonal Abs to TRAIL
(human), TRAIL-R1/DR4 and TRAIL-R2/DR5 (Axxora,
San Diego, CA, USA); polyclonal Abs against: phospho-
AKT (Ser473) and AKT; phospho-STAT3 (Tyr705) and
STAT3; phospho-c-Jun (Ser73) and c-Jun; phospho-SAPK/
JNK (Thr183/Tyr185) and JNK; phospho-p44/p42 MAP
kinase (Thr202/Tyr204) and p44/p42 MAP kinase; phos-
pho-p38 MAP kinase (Thr180/Tyr182) and p38 MAP
kinase; phospho-FOXO3A (Ser318/321) and FOXO3A;
BAX, phospho-p53 (Ser20) and p53 (Cell Signaling,
Beverly, MA, USA). Optimal dilutions of primary Abs
were 1:1000 to 1:5000. The secondary Abs anti-mouse or
anti-rabbit) were conjugated to horseradish peroxidase
(dilution 1:5000 to 1:10000); signals were detected using
the ECL system (Amersham, Piscataway, NJ, USA).
EMSA
Electrophoretic mobility shift assay (EMSA) was per-
formed for the detection of NF-jB DNA-binding activity as
previously described, using the labeled double-strand oli-
gonucleotide AGCTTGGGGACTTTCCAGCCG. (Binding
site is underlined). Ubiquitous NF-Y DNA-binding activity
was used as an internal control [25].
Statistical analysis
Data were calculated as means and standard deviations.
Comparisons of surviving fractions between treated and
control groups were made by the Students’ t-tests. A
P-value of 0.05 or less between groups was considered
significant.
Results
Effects of suppression of PI3K-AKT and COX-2
on radiosensitivity of melanoma cells
Direct c-irradiation of most melanoma cell lines is fol-
lowed by marked G2/M arrest of the cell cycle and low
levels of apoptosis 48 h after treatment (Fig. 1a for WM35
melanoma cells). Results of clonogenic survival assays
12 days after c-irradiation demonstrated, however, that
melanoma lines exhibit differential radiation resistance,
which was relatively high for SW1 murine and HHSMS
human metastatic melanoma cells, average for LU1205
human metastatic and WM35 human radial growth phase
melanoma cells, and low for WM9 human metastatic
melanoma cells (Fig. 1b and c). Most melanoma lines used
in this study possess relatively high basal levels of acti-
vated phospho-Akt (Ser473), which is involved in
protection against cell death (Fig. 1d). The only exception
was WM9 line that exhibits low to average levels of
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phospho-AKT. High AKT activity, found in WM35,
LU1205 and SW1, but not in WM9 cells, was correlated
with higher levels radioresistance of WM35, LU1205 and
SW1 cells as determined by clonogenic survival assays
(Fig. 1b, c).
Low apoptotic levels 48 h after irradiation, but pro-
nounced decreases in clonogenic survival 12 days after
treatment indicate that non-apoptotic mechanisms are
preferentially involved in regulation of radiosensitivity of
melanoma cells. The early response to c-radiation, origi-
nating from activation of the DNA damage signaling
pathways, includes p53-Ser20 phosphorylation (Fig. 2a)
via ATM-Chk2 pathway and correspondent upregulation of
p53 transcription factor activity [26]. In addition, upregu-
lation of NF-jB activity, a common protective reaction of
cells to different types of stress conditions (Fig. 2b), was
observed 3–6 h after c-irradiation of melanoma cells [10].
However, no notable activation of procaspase-3 was
detected in these conditions, confirming the absence of
induction of pronounced apoptotic signaling 6 h after
c-irradiation (Fig. 2a). Besides active phospho-AKT and
NF-jB, two main protein regulators of general cell survival
were detected in most melanoma lines at average to high
levels: COX-2 and Bcl-xL (Figs. 1d and 2a).
To decrease radioresistance of WM35 and LU1205 cells,
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Fig. 1 Radiation resistance of
melanoma cell lines. (a) Cell
cycle-apoptosis analysis of
melanoma lines WM35 48 h
after c-irradiation using PI
staining DNA and flow
cytometry. Gamma-irradiation
induces G2/M arrest of the cell
cycle, while levels of apoptosis
(Apop) are relatively low. (b, c)
Clonogenic survival assay of
human WM35, WM9, LU1205,
HHMSX and mouse SW1
melanoma lines 12 days after
c-irradiation of 1.25–5 Gy.
Error bars represent
mean ± SD from four
independent experiments.
Results of a typical experiment
are shown in (b). (d) Western
blot analysis of phospho-AKT
(Ser473), total AKT and COX-2
levels in melanoma cell lines
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COX-2, which were constituently active in WM35 and
LU1205 cells (Figs. 1d, 2a), in combination with c-irradia-
tion. An inhibitor of COX-2 (NS398, 50 lM) or PI3K-AKT
(LY294002, 50 lM) was added to WM35 and LU1205 cell
cultures immediately after c-irradiation. Both inhibitors
substantially increased levels of the G2/M arrest in irradiated
WM35 (Fig. 2c) and LU1205 cells (data not shown). Fur-
thermore, NS398 modestly enhanced upregulation of
apoptosis in irradiated WM35 cells, while LY294002, which
additionally to PI3K targets PI3K-related kinases, ATM,
ATR and DNA-PK, was more efficient at increasing the
percentage of cells in G2/M arrest (Fig. 2c). Staining WM35
melanoma cells with Annexin-V-FITC + PI and the
subsequent FACS analysis determined preferentially
necrotic response to c-irradiation in the presence of COX-2
and PI3K-AKT inhibitors (Fig. 2d). Annexin-V-positive
(apoptotic) cells were also observed at low levels 6 h after
treatment WM9 and LU125 cells (data not shown). Fur-
thermore, clonogenic survival was substantially decreased
for irradiated melanoma cells in the presence of NS398 or
LY294002 12 days after treatment, further suggesting the
occurrence of a mixed type of slow cell death, principally by
necrosis, but also involving apoptosis (Fig. 3a–c). Since
WM9 cells were intrinsically more radiosensitive, both
inhibitors notably accelerated cell death after irradiation,
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Fig. 2 Inhibition of COX-2 and PI3K-AKT activities further upreg-
ulates the G2/M arrest WM35 melanoma cells following c-irradiation.
(a) Western blot analysis of indicated proteins 6 h after irradiation.
(b) NF-jB DNA-binding activity determined by EMSA 6 h after
c-irradiation of WM35 cells. (c) Effects of c-radiation, COX-2
inhibitor NS398 (50 lM) and PI3K-AKT inhibitor LY294002
(50 lM) alone or in combination on the cell cycle of WM35
melanoma. Cells were stained with PI and analyzed by flow
cytometry. Results of a typical experiment (one of three) are
presented. (d) Effects of NS398 and LY294002 (50 lM) on
c-irradiation-induced death of WM35 cells. Apoptosis-necrosis anal-
ysis was performed by Annexin V-FITC + PI staining and the flow
cytometry. Results of a typical experiment (one of four) are presented
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To obtain additional data supporting our hypothesis that
COX-2 suppression upregulates radiation-induced level of
the G2/M arrest of the cell cycle, we established LU1205,
WM9 and WM35 mass cultures with partial suppression of
COX-2 expression levels by specific RNAi (Fig. 4a and
data not shown). Basal and radiation-induced (2.5–5 Gy)
levels of total p53 and phospho-p53 (Ser20) were substan-
tially increased after COX-2 knockdown (Fig. 4a) followed
by a corresponding increase in p53-dependent transcription
as observed by luciferase reporter analysis (data not shown).
Radiation-induced levels of G2/M arrest also were corre-
spondently higher in cells with COX-2 knockdown
(Fig. 4b). No additional effects were detected in upregula-
tion of TRAIL-R2/DR5 surface expression after irradiation
of COX-2 knockdown cells (Fig. 4c). On the other hand,
clonogenic survival analysis demonstrated a pronounced
decrease in survival of melanoma cells with suppressed
COX-2 after c-irradiation (Fig. 4d). Similar to results of
pharmacological inhibition of COX-2 activity, COX-2
knockdown increased levels of mixed, mainly non-apop-
totic, death of LU1205, WM9 and WM35 melanoma cells
(Fig. 4d and data not shown). Hence, these data demon-
strated substantial effects resulting from suppression of both
COX-2 activity and expression levels and culminating in
decreased clonogenic survival of irradiated melanoma cells.
TRAIL-induced apoptosis in c-irradiated melanoma
cells
By default, necrosis is accompanied acutely by severe
inflammation, and often chronically by fibrosis or even
organ damage, while apoptosis represents a more organized
and physiologically rapid form of cell death [27]. Could it
be possible to control the mechanism of death after c-irra-
diation of melanoma cells? As a rule, the extrinsic death
pathway can be activated in melanoma cells after appro-
priate treatment. Based on our previous results [10], we
induced TRAIL-mediated apoptosis 16 h after c-irradiation
melanoma cells. This approach was very effective for
treatment of WM35 and LU1205 cells by exogenous
recombinant TRAIL, due to an additional upregulation of
TRAIL-R2/DR5 surface levels by c-irradiation (Fig. 5a).
As expected, the presence of cycloheximide (CHX) sub-
stantially increased TRAIL-mediated apoptosis (Fig. 5b
and data not shown). Clonogenic survival assay further
confirmed high effectiveness of TRAIL treatment for
downregulation of survival of irradiated WM35 and
LU1205 melanoma cells (Fig. 5c). For intrinsically TRAIL-
sensitive WM9 cells, we observed only a small additional
benefit for upregulation of TRAIL-mediated apoptosis and
downregulation of cell survival after irradiation (Fig. 5c).
Taken together, results obtained with metastatic
LU1205 cells were relatively similar to those obtained with
radial growth phase WM35 cells (Fig. 5). Both cell lines
display average levels of radiosensitivity that could be
enhanced by combined treatment with c-irradiation and
COX-2 or PI3K-AKT inhibitors via necrotic pathways.
However, c-irradiation substantially decreased clonogenic
survival of LU1205 and WM35 after the subsequent
treatment with recombinant TRAIL via apoptotic pathway.
































































Fig. 3 Inhibition of COX-2 and PI3K-AKT decreased melanoma cell
survival following c-irradiation. (a–c) Clonogenic survival assay of
WM35, WM9 and LU1205 cells 12 days after c-irradiation of 1.25–5
Gy alone or in combination with either NS398 (50 lM) or LY294002
(50 lM). Error bars represent mean ± SD from three independent
experiments
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recombinant TRAIL decrease clonogenic survival of irra-
diated melanoma cells at potentially similar levels, there
could be a clinically relevant difference between necrotic
cancer cell death after c-irradiation in the presence of
NS398 or LY294002 and TRAIL-mediated apoptosis of
pre-irradiated melanoma cells. Could endogenous TRAIL
be induced on the surface of TRAIL-Receptor positive
melanoma cells after proper treatment for the subsequent
initiation TRAIL-mediated apoptosis?
Effects of resveratrol (RV) on TRAIL surface
expression and the main signaling pathways
in melanoma cells
Our recent finding demonstrates that resveratrol (RV), a
polyphenolic phytoalexin, may accelerate exogenous
TRAIL induced death in many melanoma cell lines [17].
Furthermore, RV by itself was an efficient inducer of
apoptotic death in some cancer cell lines [28], including
melanoma lines [17]. We observed that RV upregulated
TRAIL gene promoter activity and induced TRAIL surface
expression that was quite diverse in different melanoma
lines (Fig. 6a and b). We chose the SW1 melanoma cells,
due to its intrinsically high level of radioresistance
(Fig. 1b), but high sensitivity to RV for further investiga-
tions of the interaction of RV and TRAIL mediated
signaling.
There is a profound qualitative similarity in action of
RV on signaling pathways in human LU1205 [29] and
murine SW1 melanoma cells (Fig. 6c). Similarly to human
LU1205 cells, RV treatment downregulated NF-jB activ-
ity, phospho-Tyr-STAT3 and phospho-Ser-FOXO3A
levels, while activated MAPK’s (ERK, p38 and JNK) and
their targets cJun and ATF2 in murine SW1 cells. There
was a notable increase in AP-1/Jun2-dependent and p53-
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Fig. 4 RNAi-mediated knockdown of COX-2 expression substan-
tially increased levels of the G2/M arrested metastatic melanoma cells
and decreased cancer cell survival. (a) Suppression COX-2 expression
levels by specific RNAi affect p53 (P-Ser20) basal levels in LU1205
melanoma cells. (b) Effects of COX-2 knockdown on the cell cycle in
LU1205 and WM9 melanoma cells. PI staining and FACS analysis
were used. (c) Effects of c-irradiation on surface TRAIL-R2/DR5
levels in the control and COX-2 knockdown LU1205 cells. Immu-
nostaining with anti-DR5-PE and FACS analysis were used. (d)
Clonogenic survival assay of the control and COX-2 knockdown
LU1205 and WM9 cells after c-irradiation. Error bars represent
mean ± SD from three independent experiments
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STAT3- and NF-jB-mediated transcription in SW1 cells
following RSV treatment (Fig. 6a). RV caused opposite
effects on promoter activity of TRAIL (upregulation) and
cFLIP (downregulation) (Fig. 6a) that was accompanied by
downregulation of cFLIP-L protein levels (Fig. 6c). Fur-
thermore, Bcl-xL substantially decreased, while phospho-
p53 (Ser20) levels and levels of its target p21-WAF further
increased in SW1 cells after RSV treatment (Fig. 6a and c).
In order to determine the role of RV in elevated acti-
vation of the MAPK pathways (MEK-ERK, MKK6-p38-
ATF2, MKK4/7-JNK-cJun) in both LU1205 and SW1
melanoma cell lines, we used specific pharmacological
inhibitors: U0126 (10 lM) for MEK-ERK, SB203580
(10 lM) for p38 and SP600125 (20 lM) for JNK. Inhibi-
tion of RV-induced MEK-ERK or p38 MAPK activation
substantially accelerated apoptotic response of SW1 cells
to RV (25–50 lM), while inhibition of JNK activity did not
cause pronounced changes in apoptotic levels induced by
RV (data not shown). These data clearly demonstrated a
prosurvival function of ERK1/2, and especially MAPK p38
activation, following RV treatment of LU1205 and SW1
cells. JNK activation by RV in melanoma cells appears to
play dual proapoptotic and prosurvival roles and
suppression of JNK does not notably change the life-death
balance in RV-treated melanoma cells. Hence, RV via its
effects on the main signaling pathways in melanoma cells
resulting in strong downregulation of levels of antiapo-
ptotic proteins, such as cFLIP-L (caspase-8 inhibitor) and
Bcl-xL (Fig. 6c), can sensitize these cells to TRAIL-med-
iated apoptosis [17]. Knockdown of cFLIP levels by the
specific RNAi also sensitizes SW1 cells to TRAIL-medi-
ated apoptosis (data not shown).
Resveratrol (RV)-induced TRAIL-mediated cell suicide
in some melanoma lines
Human melanocytes and most metastatic human melano-
mas are relatively resistant to RV-induced apoptotic stimuli
(at RV doses of 25–100 lM). In contrast, SW1 mouse
melanoma cells were sensitive to RV-induced death sig-
naling, and quickly developed apoptosis at average to high
levels 16 h after treatment (Fig. 6d). In addition, levels of
apoptosis further increased 40 h after treatment. A clono-
genic survival assay confirmed 75–90% death of SW1
melanoma cells 12 days after treatment with 50–100 lM
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Fig. 5 Combined treatment of
melanoma lines with
c-irradiation and TRAIL. (a)
Effect of c-irradiation on
TRAIL-R2/DR5 surface
expression. Immunostaining
with anti-DR5-PE and FACS
analysis were used. (b).
Upregulation of TRAIL-induced
apoptosis in WM35 melanoma
cells after sequential treatment
with c-irradiation (5 Gy) and
16 h after irradiation with
recombinant TRAIL (50 ng/ml)
for an additional 24 h. Cell
cycle-apoptosis analysis was
performed using PI staining
DNA and flow cytometry. (c)
Clonogenic survival assay of
WM35, WM9 and LU1205 cells
12 days after treatment with
recombinant TRAIL (50 ng/ml)
alone or in combination with
c-irradiation of 1.25–5 Gy.
Error bars represent
mean ± SD from three
independent experiments
Apoptosis (2008) 13:790–802 797
123
mechanisms that could account for the hypersensitivity of
SW1 cells to RV: (i) dose–dependent down-regulation
STAT3- and NF-jB-dependent transcription (Fig. 6a and c),
which control expression genes with survival functions
including cFLIP-L and Bcl-xL [30, 31]; (ii) upregulation of
TRAIL promoter activity (via the JNK-cJun pathway) and
increased surface expression of endogenous TRAIL
induced by RV in a dose–dependent manner (Fig. 6b).
In conditions of suppression of STAT3-dependent gene
expression and a partial suppression of NF-jB-dependent
gene expression, endogenously produced TRAIL, via
autocrine/paracrine action, induces a receptor-mediated
death signaling cascade in TRAIL-R-positive SW1 cells,
ultimately resulting in suicide of these cells. Levels of
RV-induced death are correlated with surface expression of
endogenous TRAIL following RV treatment of melanoma
cell lines (Fig. 6b and d).
RV-induced death of SW1 cells could be blocked by an
inhibitory antibody to TRAIL (5 lg/ml) introduced into the
culture medium, but not by anti-TNF mAb, which actually
promoted RV-induced apoptosis (Fig. 6e). These data
indicate that endogenous TRAIL is the critical factor of
RV-induced apoptosis in SW1 cells. On the other hand,
endogenous TNFa appears to protect against TRAIL-
mediated apoptosis via NF-jB activation. We used a
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Fig. 6 Effects of resveratrol (RV) on cellular proteins controlling cell
survival and apoptosis in SW1 melanoma cells. (a) Effects of RV on
NF-jB-, AP-1, STAT- and p53-dependent luciferase reporter activ-
ities, TRAIL and FLIP promoter activities. (b) Effects of RV on
TRAIL surface expression in SW1 melanoma cells. Immunostaining
with anti-TRAIL-PE mAb and FACS analysis were used. (c) Effects
of RV (50 lM) on basal nuclear NF-jB and NF-Y activities in SW1
cells determined by EMSA 6 h after treatment. Positions of DNA-
binding complexes are indicated. Free labeled probes are not shown.
Western blot analysis was performed for detection of total and
phospho-protein levels of STAT3, FOXO-3A, ERK1/2, JNK1/2, cJun,
p38MAPK, ATF2, TRAIL, TRAIL-R, cFLIP, phospho-p53 (Ser20),
total p53 and p21-WAF 6 h after treatment with RV. Western blot
analysis of Bcl-xL, XIAP and b-actin levels 16 h after treatment with
RV. (d) Levels of apoptosis induced by RV (50 lM) in melanoma
lines 16 h after treatment. (e) Effects of anti-TRAIL (5 lg/ml) and
anti-TNF (5 lg/ml) inhibitory mAbs on RV-induced apoptosis in
SW1 cells. PI staining DNA and flow cytometry analysis were used
for cell cycle-apoptosis analysis. (f) Clonogenic survival assay for
combined treatment of SW1 cells by RV (0–100 lM) and Bay
11-7082 (5 lM). Error bars represent mean ± SD from three
independent experiments
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11-7082 (5 lM) fur further suppression of basal NF-jB
activity in RV-treated melanoma cells. Bay 11-7082, after
addition to the cell culture, notably increased RV-induced
apoptotic levels, highlighting a protective role of NF-jB
against RV-induced apoptosis (Fig. 6f). Taken together,
results obtained indicate that proapoptotic effects of RV
correlates with negative regulation of STAT3-, NF-jB-
mediated transcription, the correspondent suppression of
expression of antiapoptotic proteins and, finally, with
induction of surface expression of TRAIL. This expression
was substantially higher in the sensitive melanoma line
SW1, compared to WM35 or LU1205 (Fig. 6b). We have
not found a perfect human analog of SW1 melanoma,
although LOX human melanoma cells exhibit average
levels of endogenous TRAIL expression and TRAIL-
mediated apoptosis following RV treatment [17]. RV by
itself does not upregulate surface expression of death
receptors and requires an additional pretreatment of cancer
cells with c-irradiation for establishing the most optimal
conditions for induction of apoptosis.
Synergistic effects of sequential treatment of SW1
melanoma cells by c-radiation and RV
SW1 cells are relatively radioresistant, while WM35 and
LU1205 cells are notably less resistant to c-radiation
(Fig. 1c). In contrast, RV induced higher levels of apop-
tosis 16 after treatment in SW1 than in WM35 and LU1205
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4%   2%         88%
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Fig. 7 Synergistic effects of
RV and c-irradiation on
regulation of cell death in SW1
mouse and WM35 human
melanomas. (a) Effects of
c-irradiation (5 Gy), RV
(50 lM) and combined
treatment on the cell cycle and
apoptosis in SW1 cells. Cells
were stained by PI 40 h after
treatment. RSV was added 16 h
after irradiation for an
additional 24 h. Apoptosis
(Apop) levels were determined
as the percentage of cells with
hypodiploid content of DNA in
the pre-G0/G1 region using flow
cytometry; % cells at the
distinct phases of the cell cycle
is indicated. Results of typical
experiments (one of three) are
presented. (b) Effects of
c-irradiation on TRAIL and
TRAIL-R surface expression in
SW1 cells. (c) Clonogenic
survival assay of SW1 cells
12 days after indicated
treatments: RV (25–100 lM)
and c-irradiation (2.5 Gy and 5
Gy) were used. Error bars
represent mean ± SD from
three independent experiments.
(d, e) Clonogenic survival assay
of WM35 and LU1205 cells
12 days after indicated
treatments. Error bars represent
mean ± SD from three
independent experiments
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cells (Fig. 7a and data not shown). As expected, c-irradi-
ation of SW1 cells increased TRAIL-R, but did not affect
TRAIL surface expression (Fig. 7b). Finally, sequential
treatment of SW1 cells first by c-radiation to increase
surface expression of TRAIL-R, and then 16 h after irra-
diation with RV for an additional 24 h to induce
endogenous TRAIL translocation to the cell surface and to
suppress anti-apoptotic cFLIP and Bcl-xL, results in a
strong upregulation of RV-induced apoptosis (Fig. 7a) and
dramatic downregulation of SW1 clonogenic survival
(Fig. 7c). Furthermore, clonogenic survival assays dem-
onstrated substantially decreased survival for WM35 cells
after combined treatment by radiation and RV (Fig. 7d).
LU1205 cells were more resistant to RV treatment, which
did not notably change levels of radiation-induced cell
death (Fig. 7e). Optimized strategy requires treatment of
LU1205 cells with a combination of TRAIL+RV to
achieve effective killing [14].
Critical questions remain regarding: (i) how RV induces
endogenous TRAIL protein transport to the cell surface;
and (ii) why this process is so different in distinct mela-
noma lines. These are under current investigation in our
laboratory.
Discussion
Scientific observations indicate that the incidence of mel-
anoma has significantly increased over the last 40 years in
the USA and worldwide. The probability of an American
developing melanoma jumped from 1 in 1,500 in 1960, to 1
in 68 in 2000, and is projected to increase to 1 in 50 by the
year 2010 [32, 33]. There is a lack of effective treatments
for individuals with advanced disease, and the key to
improve survival remains early diagnosis and treatment
[34, 35]. Ionizing radiation is not widely used for treatment
of metastatic melanomas due to relative radioresistance and
prevalent genomic instability of this type of cancer. The
complementary approach, based on the combined treatment
of c-irradiation and inhibitors of cell survival pathways,
was quite successfully used for treatment of many types of
cancer [36], and, as demonstrated by the present study, has
potential for use in the treatment of metastatic melanoma.
One serious problem for the clinical application of this
approach is the intransigence of melanoma to p53-depen-
dent apoptotic mechanisms. Since p53 mutations are
relatively rare in melanomas [37], wild-type p53 operates
as an important transcription factor, controlling transcrip-
tion of genes whose proteins are directly involved in cell
cycle regulation and apoptosis. However, its downstream
proapoptotic function could be systematically suppressed
due to aberrancies in melanoma cellular physiology. For
example, a blockage of mitochondrial function [15] and the
mitochondrial death pathway in metastatic tumors,
including advanced melanomas, can silence the proapop-
totic function of p53. Thus, melanoma cells, injured by
c-radiation and arrested at the G2/M phase of the cell cycle,
are destined to die slowly by a necrotic mechanism. As we
observed in the present study, inhibitors of COX-2 and
PI3K-AKT may facilitate this process, still continuing to
use a necrotic mechanism.
Furthermore, one of the critical factors that determine
the efficacy of a given anticancer therapy is its ability to
maximize cancer cell death, while minimizing effects on
normal cells, thereby enhancing the therapeutic ratio.
However, cytotoxic chemotherapy and ionizing radiation
not only affect tumors, but also normal cells, especially
dividing lymphocytes that are required to develop an
antitumor immune response. In contrast to these conven-
tional therapies, TRAIL, via interaction with the
correspondent TRAIL-R1 and TRAIL-R2 on surface of
cancer cells, may induce a fatal signaling cascade in cancer
cells and have only minimal cytotoxic effects in normal
cells [7, 8]. Unfortunately, most human melanomas are
resistant to TRAIL [38]. During the last several years we
and others used different approaches to enhance sensitivity
of melanoma cells to TRAIL. Recently, we revealed that
resveratrol (RV) in combination with TRAIL may effi-
ciently increase levels of TRAIL-mediated apoptosis in
melanoma cells [29], as it was previously observed to do
for gliomas and prostate cancer [39, 40]. The striking
feature of RV treatment for some melanoma lines, which
was elucidated in the present study, was induction of
apoptotic death by itself, or in combination with c-irradi-
ation. These effects of RV appear to be based on several
critical targets of its action: (1) downregulation of NF-jB
and STAT3-dependent gene expression controlling
expression of numerous genes involved in cell survival [31,
40]; (2) the subsequent negative regulation of cFLIP and
Bcl-xL gene expression and protein stability in melanoma
cells; (3) the positive regulation of TRAIL gene expression
and TRAIL protein transport to the cell surface. The mel-
anoma lines resistant to radiation-induced cell death, such
as SW1 and HHMSX, have substantial deficiency in
mitochondrial function and the mitochondrial death path-
way. Despite inherent mitochondrial deficiencies, we have
observed, however, that the extrinsic DR5-mediated death
pathway could still be upregulated in these cells, using
pretreatment with c-irradiation that was followed by RV
treatment, which induced endogenous TRAIL translocation
and efficient apoptosis. This finding provides a potentially
important rational approach to more efficacious melanoma
treatment. We suggest that elucidation of mechanisms of
RV-induced TRAIL expression and translocation will yield
new insight for the treatment of resistant metastatic mela-
nomas. Taken together, results of our study demonstrated
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effectiveness of combined treatment of melanoma cells
with: (i) c-irradiation combined with chemical suppression
of COX-2 or PI3K-AKT; (ii) c-irradiation combined with
TRAIL; (iii) c-irradiation with the addition of RV for
radiosensitization of radioresistant melanoma lines. By the
use of TRAIL and RV as an accelerating agent, the pref-
erence for an apoptotic mechanism of cell death is largely
achieved.
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